Nonetheless, AIM2 had been shown to limit the development of colitis-associated tumors by inhibiting DNA-PK-mediated AKT activation (64), to regulate tumor progression by suppressing intestinal cell proliferation (65), and to mitigate or lower the risk of colorectal cancer through modulation of the gut microbiota (65). This evidence concerns the gene AIM2 and colitis.